Literature DB >> 22039869

Anticancer platinum (IV) prodrugs with novel modes of activity.

Chee Fei Chin1, Daniel Yuan Qiang Wong, Ramasamy Jothibasu, Wee Han Ang.   

Abstract

Over the past four decades, the search for improved platinum drugs based on the classical platinum (II)-diam(m)ine pharmacophore has yielded only a handful of successful candidates. New methodologies centred on platinum (IV) complexes, with better stability and expanded coordination spheres, offer the possibility of overcoming limitations inherent to platinum (II) drugs. In this review, novel strategies of targeting and killing cancer cells using platinum (IV) constructs are discussed. These approaches exploit the unique electrochemical characteristics and structural attributes of platinum (IV) complexes as a means of developing anticancer prodrugs that can target and selectively destroy cancer cells. Anticancer platinum (IV) prodrugs represent promising new strategies as targeted chemotherapeutic agents in the ongoing battle against cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22039869     DOI: 10.2174/156802611798040778

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  12 in total

1.  Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.

Authors:  George Mattheolabakis; Dandan Ling; Gulzar Ahmad; Mansoor Amiji
Journal:  Pharm Res       Date:  2016-08-15       Impact factor: 4.200

2.  Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity.

Authors:  Jonathan C Barnes; Peter M Bruno; Hung V-T Nguyen; Longyan Liao; Jenny Liu; Michael T Hemann; Jeremiah A Johnson
Journal:  J Am Chem Soc       Date:  2016-09-14       Impact factor: 15.419

3.  Encapsulation of Pt(IV) Prodrugs within a Pt(II) Cage for Drug Delivery.

Authors:  Yao-Rong Zheng; Kogularamanan Suntharalingam; Timothy C Johnstone; Stephen J Lippard
Journal:  Chem Sci       Date:  2015-02-01       Impact factor: 9.825

Review 4.  Carbon nanotubes as cancer therapeutic carriers and mediators.

Authors:  Kuk Hui Son; Jeong Hee Hong; Jin Woo Lee
Journal:  Int J Nanomedicine       Date:  2016-10-07

5.  Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer.

Authors:  Rongrong Zhang; Yun Ru; Yiping Gao; Jinyin Li; Shilong Mao
Journal:  Drug Des Devel Ther       Date:  2017-09-05       Impact factor: 4.162

6.  An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo.

Authors:  Josef Mayr; Petra Heffeter; Diana Groza; Luis Galvez; Gunda Koellensperger; Alexander Roller; Beatrix Alte; Melanie Haider; Walter Berger; Christian R Kowol; Bernhard K Keppler
Journal:  Chem Sci       Date:  2016-12-15       Impact factor: 9.825

7.  Induction of targeted necrosis with HER2-targeted platinum(iv) anticancer prodrugs.

Authors:  Daniel Yuan Qiang Wong; Jun Han Lim; Wee Han Ang
Journal:  Chem Sci       Date:  2015-03-16       Impact factor: 9.825

8.  Glutathione boosting the cytotoxicity of a magnetic platinum(iv) nano-prodrug in tumor cells.

Authors:  Zhenzhu Zhu; Zenghui Wang; Yigang Hao; Chengcheng Zhu; Yang Jiao; Huachao Chen; Yun-Ming Wang; Jun Yan; Zijian Guo; Xiaoyong Wang
Journal:  Chem Sci       Date:  2016-01-20       Impact factor: 9.825

Review 9.  Advances in drug delivery system for platinum agents based combination therapy.

Authors:  Xiang Kang; Hai-Hua Xiao; Hai-Qin Song; Xia-Bin Jing; Le-San Yan; Ruo-Gu Qi
Journal:  Cancer Biol Med       Date:  2015-12       Impact factor: 4.248

10.  Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action.

Authors:  Raji Raveendran; Jeremy Phillip Braude; Ezequiel Wexselblatt; Vojtech Novohradsky; Olga Stuchlikova; Viktor Brabec; Valentina Gandin; Dan Gibson
Journal:  Chem Sci       Date:  2016-01-15       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.